Krystal Biotech, Inc.

Equities

KRYS

US5011471027

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:09:28 2024-05-16 pm EDT			5-day change	1st Jan Change
164.4 ^USD	+0.73%		+3.55%	+32.49%

May. 14	Transcript : Krystal Biotech, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 02:20 PM
May. 06	Sector Update: Health Care Stocks Gain Pre-Bell Monday	MT

Krystal Biotech, Inc. Announces Resignation of Andrew Orth as Chief Commercial Officer

August 07, 2023 at 08:18 am EDT

Krystal Biotech, Inc. announced that Andrew Orth, the company?s Chief Commercial Officer, notified the company that he was resigning from his position and his last day with the Company was August 2, 2023.

Latest news about Krystal Biotech, Inc.

Transcript : Krystal Biotech, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 02:20 PM	May. 14
Sector Update: Health Care Stocks Gain Pre-Bell Monday	May. 06	MT
Krystal Biotech Swings to Q1 Profit -- Shares Fall	May. 06	MT
Transcript : Krystal Biotech, Inc., Q1 2024 Earnings Call, May 06, 2024	May. 06
Krystal Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Earnings Flash (KRYS) KRYSTAL BIOTECH Reports Q1 Revenue $45.3M, vs. Street Est of $47.4M	May. 06	MT
Futures Rise Pre-Bell Ahead of Latest Earnings Week; Asia Mostly Up, Europe Strong	May. 06	MT
North American Morning Briefing : Stock Futures -2-	May. 06	DJ
Krystal Biotech, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung	Apr. 22	CI
Stifel Adjusts Price Target on Krystal Biotech to $204 From $178, Maintains Buy Rating	Apr. 16	MT
Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing	Mar. 12	MT
Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing	Mar. 12	MT
Sector Update: Health Care Stocks Ease Late Afternoon	Feb. 26	MT
Sector Update: Health Care Stocks Weaker Monday Afternoon	Feb. 26	MT
Top Midday Gainers	Feb. 26	MT
Krystal Biotech Shares Jump After Surprise Q4 Profit	Feb. 26	MT
Krystal Biotech Swings to Q4 Profit as Company Generates Revenue; Shares Climb Pre-Bell	Feb. 26	MT
Transcript : Krystal Biotech, Inc., Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26
Krystal Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26	CI
Earnings Flash (KRYS) KRYSTAL BIOTECH Posts Q4 EPS $0.30, vs. Street Est of $-0.25	Feb. 26	MT
Krystal Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
North American Morning Briefing : Traders Await Inflation Data This Week	Feb. 26	DJ
MORNING BID AMERICAS-Booming stocks step back as PCE hoves into view	Feb. 26	RE
Krystal Biotech Says FDA Grants Fast Track Designation to Inhaled KB707 for Lung Tumors Treatment	Feb. 13	MT
Krystal Biotech Secures J-code for Vyjuvek	Jan. 04	MT

Chart Krystal Biotech, Inc.

Duration

Period

More charts

Company Profile

Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patientâs skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.

Sector

Biotechnology & Medical Research

Calendar

2024-05-17 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Krystal Biotech, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

163.2 USD

Average target price

189 USD

Spread / Average Target

+15.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KRYSTAL BIOTECH, INC.	+32.49%	4.66B
VERTEX PHARMACEUTICALS INCORPORATED	+7.74%	113B
REGENERON PHARMACEUTICALS, INC.	+10.40%	106B
ARGENX SE	+0.41%	22.27B
BIONTECH SE	-11.97%	22.22B
GENMAB A/S	-5.99%	19.43B
WUXI APPTEC CO., LTD.	-37.36%	17.87B
BEIGENE, LTD.	-5.36%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+6.88%	14.29B
SAREPTA THERAPEUTICS, INC.	+36.50%	12.52B

Bio Therapeutic Drugs